ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

RPX7009

Also written as “RPX7009 and RPX2014”, “Meropenem plus vaborbactam” and “Combination RPX7009 and RPX2014”.

Its studies are mostly in Bacterial Infections · Renal Insufficiency, led by 2 companies.

Drug pageRPX7009: every studyAll 5 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since Dec 13, 20126 company-led studies, 1 open or runningNext primary completion: Oct 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis50 open or runningphase 1since Dec 13, 2012Dec 13, 2012none ahead
Menarini Groupits history only11 open or runningphase 2since Feb 3, 2025Feb 3, 2025Oct 2027phase 2 · NCT06828848

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novartis only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 13, 2012First study: phase 1 study in Bacterial InfectionsFirst studyNCT01751269 · 80 enrolled · Australia
  2. Jan 16, 2013Phase 1 study in Bacterial InfectionsNCT01772836 · 30 enrolled · Australia
  3. Jul 9, 2013Phase 1 study in Bacterial InfectionsNCT01897779 · 94 enrolled · Australia
  4. Dec 10, 2013Phase 1 study in Subjects With Varying Degrees of Renal Insufficiency andNCT02020434 · 32 enrolled · United States
  5. Feb 14, 2014Phase 1 study in Healthy SubjectsNCT02073812 · 26 enrolled · United States

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Carbepenem-hydrolyzing beta-lactamase KPC inhibitor”ChEMBL 37, by rule

Studies

All 5 Novartis leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT02073812Healthy Subjects · United States1CompletedApr 201426
NCT02020434Subjects With Varying Degrees of Renal Insufficiency and · United States1CompletedSep 201432
NCT01897779Bacterial Infections · Australia1CompletedFeb 201494
NCT01772836Bacterial Infections · Australia1CompletedMar 201330
NCT01751269Bacterial Infections · Australia1CompletedJul 201380

How it is read

Names in the registry

  • “RPX7009”, 3 entries
  • “RPX7009 and RPX2014”, 2 entries
  • “Meropenem plus vaborbactam”, 1 entry
  • “Combination RPX7009 and RPX2014”, 1 entry

Codes read as this program: RPX7009.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.